Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01198821 · ClinicalTrials.gov registry record · Phase 1
Gem-TABS in Unresectable Pancreatic Carcinoma
A Phase 1 study, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- Completed
- Registry status
- Phase 1
- Development phase
- 8
- Enrollment target
NCT01198821 is a Phase 1 study that has completed, run by H. Lee Moffitt Cancer Center and Research Institute. The registered enrollment target is 8 participants.
The verdict
NCT01198821, a Phase 1 study, has completed, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 8 participants
- Enrollment target
Study Summary
The purpose of this study is to: Find out the largest dose of sodium bicarbonate that can be given with gemcitabine. Determine if the combination of sodium bicarbonate and gemcitabine produces better control of pancreatic cancer than gemcitabine alone.
Interventions
- DRUG Gemcitabine (mg/m²)
- DRUG Sodium bicarbonate (g/kg/day)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2010-08 |
| Est. Completion | 2011-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01198821
The ClinicalTrials.gov registry entry for NCT01198821 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is H. Lee Moffitt Cancer Center and Research Institute, which has 502 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Gemcitabine (mg/m²) is the first listed.
NCT01198821 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01198821 about?
NCT01198821 is a clinical study titled "Gem-TABS in Unresectable Pancreatic Carcinoma". The purpose of this study is to: Find out the largest dose of sodium bicarbonate that can be given with gemcitabine. Determine if the combination of sodium bicarbonate and gemcitabine produces better control of pancreatic cancer than gemcitabine alone.
What is the current status of trial NCT01198821?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 8 participants. The study started on 2010-08. Estimated completion is 2011-06.
What interventions are being tested in trial NCT01198821?
The interventions under investigation include: Gemcitabine (mg/m²) (DRUG), Sodium bicarbonate (g/kg/day) (DRUG).
Who is sponsoring clinical trial NCT01198821?
This trial is sponsored by H. Lee Moffitt Cancer Center and Research Institute, which has 502 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.